Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

2026 data Public-data reference. official source

Testicular Cancer

Open-data reference.

12 US clinical trials · 8 currently recruiting

Active & Recent Trials

RECRUITING NA 260 participants

Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors

Duke University

NCT06371768

RECRUITING NA 250 participants

A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors

University of California, Irvine

NCT05836688

RECRUITING Phase 3 142 participants

Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.

Indiana University

NCT06593665

RECRUITING NA 80 participants

Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal Orchiectomy

Loma Linda University

NCT06828185

RECRUITING Phase 1 80 participants

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Context Therapeutics

NCT06515613

RECRUITING Phase 2 35 participants

A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

Wake Forest University Health Sciences

NCT06866964

RECRUITING Phase 1 30 participants

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

University of Arizona

NCT06814496

RECRUITING NA 10 participants

A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

Dana-Farber Cancer Institute

NCT05899361

ACTIVE NOT RECRUITING NA 70 participants

Pursuing Exploration Into the Supportive Care Needs and Intervention Preferences of Survivors of Testicular Cancer

Indiana University

NCT07228637

COMPLETED Phase 2 64 participants

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

M.D. Anderson Cancer Center

NCT00936936

COMPLETED Phase 1 14 participants

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

Nasser Hanna

NCT02429466

COMPLETED 10 participants

Role of Axumin PET Scan in Germ Cell Tumor

University of Texas Southwestern Medical Center

NCT03426865

Phase Distribution

PhaseTrial count
Early Phase 1 3
Phase 2 2
Phase 3 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Testicular Cancer Trial Landscape

ClinicalTrials.gov lists 12 US studies indexed under Testicular Cancer, and 8 of those are currently open to recruitment — roughly 67% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Testicular Cancer shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 5 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Testicular Cancer is led by Indiana University with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 12 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Testicular Cancer?

PlainTrial tracks 12 US clinical trials for Testicular Cancer, of which 8 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Testicular Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →